These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 32817209)

  • 21. Intratumoral Foxp3
    Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
    Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
    Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
    Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
    Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
    Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
    Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
    Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritumoral TIGIT
    Liu H; Wu J; Xu X; Wang H; Zhang C; Yin S; He Y
    Int Immunopharmacol; 2022 Jul; 108():108735. PubMed ID: 35405596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
    Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
    [No Abstract]   [Full Text] [Related]  

  • 27. Blockade of DC-SIGN
    Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
    Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
    Front Immunol; 2021; 12():793992. PubMed ID: 35145509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 30. Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis.
    Li S; Li L; Pan T; Li X; Tong Y; Jin Y
    Front Immunol; 2022; 13():977016. PubMed ID: 36211383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-infiltrating CD36
    Ao YQ; Gao J; Zhang LX; Deng J; Wang S; Lin M; Wang HK; Ding JY; Jiang JH
    BMC Cancer; 2023 Apr; 23(1):367. PubMed ID: 37085798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
    Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
    Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
    Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-infiltrating podoplanin
    Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
    Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
    Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
    Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and Prognostic Significance of LAG-3, TIGIT, VISTA, and IDO1 in Endometrial Serous Carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Lea J; Panwar V; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2024 Aug; 37(8):100532. PubMed ID: 38848896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TIGIT enhances CD4
    Chen F; Xu Y; Chen Y; Shan S
    Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.